Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren S., Eskazan A. E. , Suzan V., Savci S., Ozunal I. E. , Berk S., ...More

Hematology (Amsterdam, Netherlands), vol.23, no.4, pp.212-220, 2018 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1080/10245332.2017.1385193
  • Title of Journal : Hematology (Amsterdam, Netherlands)
  • Page Numbers: pp.212-220


Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.